Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Operating Leases: 2019-2025

Historic Operating Leases for Puma Biotechnology (PBYI) over the last 7 years, with Sep 2025 value amounting to $7.3 million.

  • Puma Biotechnology's Operating Leases fell 11.56% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 11.56%. This contributed to the annual value of $1.5 million for FY2024, which is 78.76% down from last year.
  • Per Puma Biotechnology's latest filing, its Operating Leases stood at $7.3 million for Q3 2025, which was up 68.10% from $4.4 million recorded in Q2 2025.
  • Puma Biotechnology's Operating Leases' 5-year high stood at $20.4 million during Q3 2021, with a 5-year trough of $1.5 million in Q4 2024.
  • In the last 3 years, Puma Biotechnology's Operating Leases had a median value of $8.3 million in 2024 and averaged $8.8 million.
  • Data for Puma Biotechnology's Operating Leases shows a maximum YoY tumbled of 78.76% (in 2024) over the last 5 years.
  • Over the past 5 years, Puma Biotechnology's Operating Leases (Quarterly) stood at $16.0 million in 2021, then dropped by 25.92% to $11.8 million in 2022, then slumped by 40.56% to $7.0 million in 2023, then plummeted by 78.76% to $1.5 million in 2024, then dropped by 11.56% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $4.4 million for Q2 2025, and $5.7 million during Q1 2025.